FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists Due to Potential Increased Risk of Rare But Serious Eye Condition

https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential